<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04129008</url>
  </required_header>
  <id_info>
    <org_study_id>2019026</org_study_id>
    <nct_id>NCT04129008</nct_id>
  </id_info>
  <brief_title>GaStroEsophageal effeCt of indobUfen Versus aspiRin in Patients Undergoing Dual antiplatElet Therapy</brief_title>
  <acronym>SECURE</acronym>
  <official_title>Effect of Indobufen Versus Aspirin on Gastric Acid Secretion and Gastroesophageal Reflux in Patients With Coronary Heart Disease and Gastroesophageal Reflux Disease Undergoing Dual Antiplatelet Therapy: a Prospective, Randomized, Double-blind, Double-dummy, Positive Drug Parallel Control Clinical Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The dual antiplatelet therapy based on aspirin plays an important role in the treatment of&#xD;
      patients with coronary heart disease. Although aspirin is widely used and effective, it has&#xD;
      many limitations in the long-term including increased risk of bleeding. In patients with&#xD;
      coronary heart disease and gastroesophageal reflux disease, the symptoms of gastroesophageal&#xD;
      reflux are usually aggravated after the application of aspirin. As an antiplatelet drug,&#xD;
      indobufen can reversibly and selectively inhibit platelet cyclooxygenase-1 (COX-1), thereby&#xD;
      blocking the synthesis of thromboxane B2 (TXB2) and exerting its antiplatelet effect, and it&#xD;
      does not affect the production of prostaglandins and endothelial prostacyclins in&#xD;
      gastrointestinal mucosa. It has less gastrointestinal injury and lower risk of bleeding. This&#xD;
      project is to study the effects of indobufen or aspirin on gastric acid secretion and&#xD;
      gastroesophageal reflux in patients with coronary heart disease and gastroesophageal reflux&#xD;
      disease treated with dual antiplatelet therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">October 17, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage time of intragastric pH&lt;4.0 during 24-hour intragastric pH monitoring</measure>
    <time_frame>2 weeks±4 days</time_frame>
    <description>This parameter will be detected by 24-hour intragastric pH monitoring (Medical Measurement Systems, Netherlands)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median value of intragastric pH during 24-hour intragastric pH monitoring</measure>
    <time_frame>2 weeks±4 days</time_frame>
    <description>This parameter will be detected by 24-hour intragastric pH monitoring (Medical Measurement Systems, Netherlands)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of indigestion occurrence</measure>
    <time_frame>2 weeks ±4 days, 12 weeks±7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of bleeding events (BARC criteria)</measure>
    <time_frame>2 weeks ±4 days, 12 weeks±7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastroesophageal reflux disease questionnaire score (GerdQ score)</measure>
    <time_frame>2 weeks ±4 days, 12 weeks±7 days</time_frame>
    <description>Min 0, max 18, and higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AA-induced platelet inhibition rate (TEG method)</measure>
    <time_frame>2 weeks ±4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADP-induced platelet inhibition rate (TEG method)</measure>
    <time_frame>2 weeks ±4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DeMeester score</measure>
    <time_frame>2 weeks ±4 days</time_frame>
    <description>Min 0, no upper limit, and higher scores mean a worse outcome</description>
  </secondary_outcome>
  <other_outcome>
    <measure>AA-induced platelet inhibition rate (LTA method)</measure>
    <time_frame>2 weeks±4 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>ADP-induced platelet inhibition rate (LTA method)</measure>
    <time_frame>2 weeks±4 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rate of major adverse cardiovascular event (MACE, including all-cause death, non-fatal myocardial infarction, ischemic stroke, ischemia-driven revascularization, or rehospitalization for heart failure)</measure>
    <time_frame>2 weeks±4 days, 12 weeks±7days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rate of single endpoint of cardiovascular events, including cardiovascular death, non-fatal myocardial infarction, ischemic stroke, ischemic-driven revascularization, rehospitalization for heart failure, and all-cause death</measure>
    <time_frame>2 weeks±4 days, 12 weeks±7days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Indobufen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indobufen and aspirin mimetic</intervention_name>
    <description>Day 1 to 84±7: The first time: indobufen 100mg + aspirin mimetic; The second time: indobufen 100mg</description>
    <arm_group_label>Indobufen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin and indobufen mimetic</intervention_name>
    <description>Day 1 to 84±7: The first time : aspirin 100mg+ indobufen mimetic; The second time: indobufen mimetic</description>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-75 years&#xD;
&#xD;
          -  Patients with stable and unstable angina pectoris receiving dual antiplatelet therapy&#xD;
             (combined with clopidogrel)&#xD;
&#xD;
          -  Coronary angiography indicating ≥50% stenosis in &gt;2.0 mm vessels&#xD;
&#xD;
          -  Gastroesophageal Reflux Disease Diagnostic Questionnaire Score (≥8)&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute myocardial infarction within 1 month before admission&#xD;
&#xD;
          -  Patients undergoing treatment related to gastroesophageal reflux disease (e.g. proton&#xD;
             pump inhibitors, etc.)&#xD;
&#xD;
          -  Patients receiving other antiplatelet drugs (such as cilostazol) and oral&#xD;
             anticoagulants&#xD;
&#xD;
          -  Patients with cardiogenic shock (systolic blood pressure &lt;90 mmHg and/or diastolic&#xD;
             blood pressure &lt;60 mmHg), severe heart failure (killip grade ≥3), hepatic&#xD;
             insufficiency (AST/ALT more than twice the upper limit of normal value caused by&#xD;
             non-cardiac diseases), prior stroke and renal dysfunction (GFR &lt;60 ml/min)&#xD;
&#xD;
          -  Those with active hemorrhage, hemorrhagic diseases or tendency to bleeding, especially&#xD;
             those with a history of cerebral hemorrhage&#xD;
&#xD;
          -  People who are known to be intolerant or allergic to aspirin, indobufen or clopidogrel&#xD;
&#xD;
          -  Patients with malignant tumors or with life expectancy &lt;2 years&#xD;
&#xD;
          -  Pregnant women, lactating women, women of childbearing age who do not take effective&#xD;
             contraceptive measures, or those who plan to conceive during the trial, or those who&#xD;
             have positive results of HCG examination before the trial&#xD;
&#xD;
          -  Those who have participated in other clinical trials or are currently participating in&#xD;
             other clinical trials within one month before the trial&#xD;
&#xD;
          -  According to the judgement of the researchers, patients could not complete the study&#xD;
             or comply with the requirements of the study (e.g. memory or behavioral disorders,&#xD;
             mental disorders, alcohol dependence, prior defaults)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shao-Ping Nie, MD, PhD</last_name>
    <phone>86-10-84005256</phone>
    <email>spnie@ccmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiao Wang, MD</last_name>
    <phone>86-10-84005255</phone>
    <email>spaceeye123@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shao-Ping Nie, MD, PhD</last_name>
      <phone>86-10-84005256</phone>
      <email>spnie@ccmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Huangtai Miao</last_name>
      <phone>86-10-84005255</phone>
      <email>miaohuangtai@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 8, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>October 14, 2019</last_update_submitted>
  <last_update_submitted_qc>October 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Shao-Ping Nie</investigator_full_name>
    <investigator_title>Professor of Medicine, Director, Emergency &amp; Critical Care Center</investigator_title>
  </responsible_party>
  <keyword>coronary heart disease</keyword>
  <keyword>gastroesophageal reflux disease</keyword>
  <keyword>indobufen</keyword>
  <keyword>aspirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Esophagitis, Peptic</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Indobufen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

